Cash-Strapped iMDx Launches Public Offering With Stock at 52-Week Low
IMDX is trading near its 52-week low of $1.85 (0.5% below the low).
Summary
iMDx kicked off an underwritten public offering of common stock and pre-funded warrants, with Lake Street Capital Markets as sole bookrunner and a 30-day option for up to 15% more shares. No size or pricing was disclosed, so the dilution overhang is open-ended until terms print. The timing is rough: the stock closed at $1.84, essentially at its 52-week low of $1.85, and the company just reported a Q2 loss of $11.3M on $239K of revenue with $17.8M in cash and a going-concern flag. Proceeds are earmarked for working capital and R&D in the transplantation category, which is where the GraftAssureDx FDA decision sits. This follows the September 8-K amending the Chronix merger agreement to replace the ongoing 10% CNI Monit obligation — another sign of balance-sheet pressure.
At the time of this announcement, IMDX was trading at $1.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.9M. The 52-week trading range was $1.85 to $7.92. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.